{
  "id": 15797461,
  "title": "Low vitamin D use in patients on enzyme-inducing antiseizure drugs raises concerns",
  "url": "https://urgent.news/2026/10/20/low-vitamin-d-use-in-patients-on-enzyme-inducing-antiseizure-drugs",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-20T20:50:01.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-10-vitamin-d-patients-enzyme-antiseizure.html"
  },
  "original_language": "en",
  "account": "A study presented at the American Neurological Association conference highlights concerns over low vitamin D use in patients on enzyme-inducing antiseizure drugs (ASDs). These drugs have been linked to an increased risk of osteoporosis or osteopenia, but vitamin D supplementation is underutilized, according to Dr. Mehreen Ali from Carle Illinois College of Medicine. The research used data from the All of Us Research Program, comparing 1,395 adults on enzyme-inducing ASDs to 15,374 adults on non-enzyme-inducing ASDs. The findings showed that enzyme-inducing ASD use was independently associated with a higher odds of incident osteoporosis or osteopenia, even after adjusting for various factors such as age, sex, corticosteroid use, chronic kidney disease, obesity, and vitamin D supplementation.\n\nInterestingly, only 20.7% of patients on enzyme-inducing ASDs received vitamin D supplementation postdiagnosis, compared to 16.2% of patients on non-enzyme-inducing ASDs. This discrepancy suggests a significant gap between guidelines and clinical practices, with vitamin D supplementation being a crucial factor in preventing bone disease.",
  "summary": "Enzyme-inducing antiseizure drugs (ASDs) are associated with increased odds of incident osteoporosis or osteopenia, but vitamin D supplementation is underutilized, according to a study presented at the annual meeting of the American Neurological Association, held from Oct. 17 to 20 in San Diego.",
  "key_points": [
    "Low vitamin D use in enzyme-inducing ASD patients raises concerns",
    "Only 20.7% of enzyme-inducing ASD patients receive vitamin D supplementation",
    "Vitamin D supplementation crucial for preventing bone disease"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}